Dashboard
1
With a growth in Net Profit of 64.2%, the company declared Very Positive results in Dec 25
- ROCE(HY) Highest at 13.47%
- DEBTORS TURNOVER RATIO(HY) Highest at 9.84 times
- INTEREST COVERAGE RATIO(Q) Highest at 347,453.25
2
With ROE of 8.80%, it has a fair valuation with a 4.84 Price to Book Value
3
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,045 Million (Small Cap)
55.00
NA
1.71%
-0.54
12.27%
5.59
Revenue and Profits:
Net Sales:
192 Million
(Quarterly Results - Dec 2025)
Net Profit:
30 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.77%
0%
-2.77%
6 Months
-3.71%
0%
-3.71%
1 Year
25.95%
0%
25.95%
2 Years
21.1%
0%
21.1%
3 Years
-11.42%
0%
-11.42%
4 Years
-20.93%
0%
-20.93%
5 Years
-20.61%
0%
-20.61%
Shandong Wohua Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-4.25%
EBIT Growth (5y)
-14.62%
EBIT to Interest (avg)
56.40
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.56
Sales to Capital Employed (avg)
1.11
Tax Ratio
18.74%
Dividend Payout Ratio
160.43%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
24.88%
ROE (avg)
12.98%
Valuation key factors
Factor
Value
P/E Ratio
55
Industry P/E
Price to Book Value
4.84
EV to EBIT
47.06
EV to EBITDA
32.03
EV to Capital Employed
10.09
EV to Sales
4.05
PEG Ratio
0.38
Dividend Yield
1.93%
ROCE (Latest)
21.44%
ROE (Latest)
8.80%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
192.30
199.30
-3.51%
Operating Profit (PBDIT) excl Other Income
38.90
27.20
43.01%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
29.80
17.80
67.42%
Operating Profit Margin (Excl OI)
162.60%
97.90%
6.47%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is -3.51% vs -3.95% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 67.42% vs -6.81% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
807.10
750.90
7.48%
Operating Profit (PBDIT) excl Other Income
123.70
66.70
85.46%
Interest
0.10
0.10
Exceptional Items
-1.30
-0.10
-1,200.00%
Consolidate Net Profit
88.80
33.80
162.72%
Operating Profit Margin (Excl OI)
115.10%
45.50%
6.96%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 7.48% vs -16.03% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 162.72% vs -27.47% in Dec 2024
About Shandong Wohua Pharmaceutical Co., Ltd. 
Shandong Wohua Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






